<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267305</url>
  </required_header>
  <id_info>
    <org_study_id>SICUTEG-01</org_study_id>
    <nct_id>NCT01267305</nct_id>
  </id_info>
  <brief_title>The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery</brief_title>
  <official_title>The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of different dose of LMWH compared
      with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TEG values</measure>
    <time_frame>three days after surgery</time_frame>
    <description>1.5ml aterial blood sample will be obtained daily for TEG , and the vulues of TEG,such as R,K,Alpha angle,MA,G,CI ,will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding quantity of chest drainage</measure>
    <time_frame>three days after surgery</time_frame>
    <description>all drain from chest tube are gathered and hematocrits are measured to calculate the quantities of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of deep venous thromboembolismï¼ˆDVT)</measure>
    <time_frame>after surgery up to 7 days</time_frame>
    <description>incidence of DVT is measured by vascular ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inhospital mortality</measure>
    <time_frame>after surgery up to 28 days</time_frame>
    <description>the number of death in the period of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>lung lmwh1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use LMWH once daily after lung resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lung lmwh2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use LMWH twice daily after lung resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lung Fondaparinux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use Fondaparinux once daily after lung resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eso lmwh1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use LMWH once daily after esophagectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eso lmwh2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use LMWH twice daily after esophagectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eso Fondaparinux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use Fondaparinux once daily after esophagectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>2.5mg IH qd(8AM) after operation</description>
    <arm_group_label>lung Fondaparinux</arm_group_label>
    <arm_group_label>eso Fondaparinux</arm_group_label>
    <other_name>ARIXTRA</other_name>
    <other_name>H20080111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin Calcium</intervention_name>
    <description>4100AxaIU IH qd(8AM) after operation</description>
    <arm_group_label>lung lmwh1</arm_group_label>
    <arm_group_label>eso lmwh1</arm_group_label>
    <other_name>Fraxiparine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin Calcium</intervention_name>
    <description>4100AxaIU IH q12h(8Am,8Pm) after operation</description>
    <arm_group_label>lung lmwh2</arm_group_label>
    <arm_group_label>eso lmwh2</arm_group_label>
    <other_name>Fraxiparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of esophageal carcinoma and planned for esophagectomy

          -  clinical diagnosis of lung carcinoma and planned for lung resection

          -  general anesthesia combined with epidural anesthesia

        Exclusion Criteria:

          -  blood clotting disfunction before surgery

          -  anticoagulating or antiplatelet history before surgery

          -  low blood platelets count

          -  hemorrhagic disease

          -  cerebral hemorrhage

          -  cerebral,spinal,ophthalmologic operation history

          -  peptic ulcer

          -  bleeding&gt;400ml in operation

          -  bleeding&gt;100ml/h after operation

          -  blood transfusion in or after operation

          -  severe renal or liver disfunction

          -  severe hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhen Xuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2010</study_first_submitted>
  <study_first_submitted_qc>December 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>April 28, 2014</last_update_submitted>
  <last_update_submitted_qc>April 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Ming Zhong</investigator_full_name>
    <investigator_title>department of anesthesiology and surgical intensive care unit</investigator_title>
  </responsible_party>
  <keyword>esophagectomy</keyword>
  <keyword>lung resection</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>chest drainage</keyword>
  <keyword>TEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

